Drs. Weiss, Borghaei, and Patel discuss the clinical data and practical implications for using checkpoint inhibitors to treat lung cancer.
This activity is intended for hematology and oncology specialists, pulmonologists and pathologists.
The goal of this activity is to provide insight on how recently published clinical trials on immune checkpoint inhibitors should be incorporated into practice.
Approximate Time to Complete: 40 minutes
Course Available Beginning: Aug. 24, 2016
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Evaluate emerging clinical trial data on the use of immune checkpoint inhibitors in the management of lung cancer
- Summarize the potential impact of recent clinical data on treatment strategies for patients with lung cancer in the community oncology setting